drugset / Trial / NCT05445440

A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine

NCT05445440

Phase 1 Completed 30 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of BMS-986371 on the drug levels of methotrexate, sulfasalazine and their main metabolites in healthy male adult participants.

Timeline

Start
2022-09-06
Primary completion
2022-11-17
Completion
2022-11-23

Drugs

EvaluationDrugModalityDoseRoute
Subject GAMCEMETINIB Small molecule
Subject Methotrexate Small molecule
Subject Sulfasalazine Small molecule
Background Leucovorin Small molecule

Indications

No indication recorded.